EDIUNET Free equity investment tool of Japanese companies

Companies Cart
@
Credit Rating Analysis
Annual
First quarter
Second quarter
Third quarter
Sponsored Link
Related Company
@ Sumitomo Seika Chemicals
@ TAIKO PHARMACEUTICAL
@ JSP
@ EBARA-UDYLITE 
@ FUJIKURA KASEI
@ DAINICHISEIKA COLOR & CHEMICALS MFG.
@ MATSUMOTO YUSHI-SEIYAKU
@ KUREHA
@ 和光純薬工業
@ 日本新薬
@ C.Uyemura
@ AIR WATER
@ DAISO
@ ZERIA PHARMACEUTICAL
@ 日本曹達
EDIUNET Related Ranking
EDIUNET
EDIUNET Credit Rating
EDIUNET Industry Avg
EDIUNET Prefectures
Yuho! Industry
EDIUNET Rating News
Prev « 2024-03 » Next
Mon Tue Wed Thu Fri Sat Sun
1
-
2
-
3
-
4
-
5
-
6
-
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
-
15
-
16
-
17
-
18
-
19
-
20
-
21
-
22
-
23
-
24
-
25
-
26
-
27
-
28
-
29
-
30
-
31
-
[Update list]
1/28 Retail Trade (CAWACHI:A etc...
1/27 Banks (The Awa Bank:BBB→A)
1/23 Chemicals (Milbon:AA→AAA)
1/21 Glass & Ceramics Products (..
1/21 Machinery (TSUDAKOMA:C)
1/21 Other Services (Netindex.:CC)
1/20 Other Products (Kurogane Kos..
1/20 Wholesale Trade (リーバイ・..
1/20 Other Services (川崎地質:BB→..
1/17 Chemicals (Kawaguchi Chemica..
 RSS
 Company RSS
 Daily RSS
Sponsored Link
Recently Download Chart
SANKEI CHEMICAL
graph
メルコホールディングス
graph
Renesas Electronics
graph
Hitachi Zosen etc.
graph
PIONEER
graph

Credit Rating Analysis: Eisai (Annual )

The details of credit rating (bankruptcy risk) can be checked. A credit rating in nine stages (AAA-C).

【Analysis Menu】 @Outline @Statement @Rating @Indicator @Download

Sponsored Link

Credit Rating (Bankruptcy Risk): Eisai (Annual ) Consolidated | Non-Consolidated

Date Credit Rating Comment Sales Current Profit Net Income
2013-03-31  BBB  Credit is enough, but be decreased potential by biz environs. ¥ 573 B
-11.46%
¥ 65 B
-27.16%
¥ 48 B
-17.49%

Financial Timeline

Date  2012-12-31 
(Third quarter )
 2013-03-31 
(Annual )
 2013-06-30 
(First quarter )
 2013-09-30 
(Second quarter )
Credit Rating BBBBBBBBA
Total Assets
¥ 968 B
¥ 990 B
¥ 939 B
¥ 952 B
Net Assets
¥ 429 B
¥ 474 B
¥ 477 B
¥ 494 B

Financial Statement Risk Analysis: Eisai (Annual ) (Consolidated )

[Date: 2013-03-31]  Danger : Warning : Caution : Good
Management Risk (*Sales is decrease )
Sales (¥ 573 B) is first term Sales (¥ 647 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Income is decrease )
Net Income (¥ 48 B) is first term Net Income (¥ 58 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (8.42%) is first term Net Profit Margin (9.03%) less , there is a possibility that the profitability has deteriorated.
Dividend
Under the situation of Net Income (¥ 48 B) & Operating Cash Flow (¥ 73 B) , Dividend (¥ -42 B) is paid.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 20 B) is Sales first term ratio (¥ -74 B) more , there is a possibility that the non-performing asset was increased.
[Date: 2012-03-31]  Danger : Warning : Caution : Good
Management Risk (*Sales is decrease )
Sales (¥ 647 B) is first term Sales (¥ 768 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Income is decrease )
Net Income (¥ 58 B) is first term Net Income (¥ 67 B) less , there is a possibility that the management situation has stagnated and deteriorated
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -2 B) & Financial Cash Flow (¥ -77 B) is a minus, Operating Cash Flow (¥ 90 B) is a plus,
Dividend
Under the situation of Net Income (¥ 58 B) & Operating Cash Flow (¥ 90 B) , Dividend (¥ -42 B) is paid.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ 23 B) is Sales first term ratio (¥ -120 B) more , there is a possibility that the non-performing asset was increased.
[Date: 2011-03-31]  Danger : Warning : Caution : Good
Management Risk (*Sales is decrease )
Sales (¥ 768 B) is first term Sales (¥ 803 B) less , there is a possibility that the management situation has stagnated and deteriorated
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -58 B) & Financial Cash Flow (¥ -68 B) is a minus, Operating Cash Flow (¥ 123 B) is a plus,
Dividend
Under the situation of Net Income (¥ 67 B) & Operating Cash Flow (¥ 123 B) , Dividend (¥ -42 B) is paid.
Non-performing asset Risk (*Accounts Receivable and Inventory, etc. confirmed content)
Other Current Assets first term ratio (¥ -12 B) is Sales first term ratio (¥ -34 B) more , there is a possibility that the non-performing asset was increased.
[Date: 2010-03-31]  Danger : Warning : Caution : Good
Management Risk (*Net Income is decrease )
Net Income (¥ 40 B) is first term Net Income (¥ 47 B) less , there is a possibility that the management situation has stagnated and deteriorated
Management Risk (*Net Profit Margin is decrease )
Net Profit Margin (5.02%) is first term Net Profit Margin (6.10%) less , there is a possibility that the profitability has deteriorated.
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -69 B) & Financial Cash Flow (¥ -49 B) is a minus, Operating Cash Flow (¥ 107 B) is a plus,
Dividend
Under the situation of Net Income (¥ 40 B) & Operating Cash Flow (¥ 107 B) , Dividend (¥ -39 B) is paid.
[Date: 2009-03-31]  Danger : Warning : Caution : Good
Financing Good (*Operating Cash Flow is plus )
Investment Cash Flow (¥ -54 B) & Financial Cash Flow (¥ -30 B) is a minus, Operating Cash Flow (¥ 104 B) is a plus,
Dividend
Under the situation of Net Income (¥ 47 B) & Operating Cash Flow (¥ 104 B) , Dividend (¥ -38 B) is paid.

Ticker Market Industry Month report Rating
@ Eisai 4523 TSE 1st Chemicals 3 Annual BBB

Related Company

@ SANYO CHEMICAL INDUSTRIES (Sales ¥ 142 B)
@ DAISO (Sales ¥ 83 B)
@ MATSUMOTO YUSHI-SEIYAKU (Sales ¥ 27 B)
@ POLA ORBIS HOLDINGS (Sales ¥ 180 B)
@ MUTO SEIKO CO. (Sales ¥ 24 B)
@ Daito Pharmaceutical Co . (Sales ¥ 28 B)
@ EBARA-UDYLITE  (Sales ¥ 14 B)
@ AIR WATER (Sales ¥ 540 B)
@ タキロン (Sales ¥ 67 B)
@ ZERIA PHARMACEUTICAL (Sales ¥ 53 B)
@ KUREHA (Sales ¥ 130 B)
@ 和光純薬工業 (Sales ¥ 74 B)
@ ZEON (Sales ¥ 250 B)
Sponsored Link


関連する株式投資情報

EDIUNET Caution

*Financial data might be different from the actual one. Please confirm the original, and read Caution.

*This site has obtained the information from the FSA's EDINET, Tokyo Stock Exchange's TDnet and Pay statistical data services, Fukuoka stock Exchange's Stock market capitalization, Center for Spatial Information Science's CSV Geocoding Service. The copyright of the information belongs to each corporation etc. .

▲ Go to the top ▲

  1. Guide
  2. Mobile
  3. Tablet
  4. Japanese
`EDIUNET` Copyright©2006-2024 `MAバンク` (0.096 sec.)